CompletedNot Applicable

Case Series : Management of Elevated Lipoprotein(a) Using Double-Filtration Plasmapheresis (DFPP) in Hemodialysis Patients With Chronic Kidney Disease ; ( LiPo-A )

France5 participantsStarted 2025-07-01

Plain-language summary

Lipoprotein-apheresis DFPP has been performed in patients with Lp(a) levels greater than 125 nmol/L. In this report, data will be presented on five hemodialysis patients with significantly elevated Lp(a) levels (\>200 nmol/L) who had a history of cardiovascular disease and notable thromboembolic events.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Chronic hemodialysis patients with elevated Lp(a) levels (\>200 nmol/L) and a history of cardiovascular disease and/or thromboembolic events who underwent DFPP sessions as part of their management Exclusion Criteria: * -Patients with progressive, active disease, presenting with severe general deterioration and a limited life expectancy * Patients presenting with hemodynamic instability * Patients presenting with acute kidney diseases.

What they're measuring

serum Lp(a) concentration (nmol/L), on routine venous blood sampling

Timeframe: up to 15 months after inclusion

Trial details

NCT IDNCT07390604

SponsorCentre Hospitalier Régional Metz-Thionville

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-09-30

View on ClinicalTrials.gov More Lipoprotein(a) trials